June 4, 2026
Supporting Innovation in Friedrich Ataxia Clinical Research
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Register Your Interest
English
Doherty Clinical Trials will be attending BIO International Convention in Boston June 5 - 8 2023. We look forward to meeting you there!
The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.
Visit the BIO International Convention website for further information.
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Doherty Clinical Trials Limited is proud to announce the commencement of the CHIVAS-M1 study (Controlled Human Infection for Vaccination Against Streptococcus pyogenes M1UK), which will help drive medical research and development of a vaccine against Streptococcus pyogenes, otherwise known as Strep A.
Senior Lab Manager, Vanessa Mollard represented Doherty Clinical Trials at the forum in Canberra
Dr Andrew Brockway's panel, 'Clinical Trials in Australia: Performance, Competitive Advantages, Challenges and Evolving Policy' at AusBiotech 2024
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}